CardioNet Announces Public Offering of Common Stock.

CONSHOHOCKEN, Pa. -- CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced an underwritten public offering of 4,664,102 shares of common stock by certain of CardioNet's existing stockholders. The selling stockholders plan to grant to the underwriters an option to purchase from them an additional 699,615 shares to cover over-allotments, if any. CardioNet will not be selling any shares of common stock in the offering and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Citi is the sole book-running manager, Banc of America Securities LLC and Leerink Swann are the co-lead managers and Cowen and Company and Thomas Weisel Partners LLC are the co-managers for this offering. A prospectus relating to these securities may be obtained from the Prospectus Department of Citi by calling [phone], by emailing [e-mail] or by writing to Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a high degree of risk and uncertainty. In particular, due to market conditions or otherwise the selling stockholders may be unable to complete the sale of common stock under the registration statement, and, even if such sale is completed, the underwriters for the offering may not exercise any portion of the over-allotment option.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. CardioNet's initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as the CardioNet System. More information can be found at http://www.cardionet.com.